Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses

Research Communications in Molecular Pathology and Pharmacology

Volumn 117-118, Issue , 2005, Pages 47-63

  Giri, Shri N ^a   Margolin, Solomon B ^a  

^a Marnac Inc   (United States)

Author keywords

Cytokines; Equine; Inflammation; Lameness; Pirfenidone

Indexed keywords

PIRFENIDONE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL LAMENESS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA; GELDING; HAIR LOSS; HORSE DISEASE; HYPERTHERMIC THERAPY; INFLAMMATION; JOINT LIMITATION; LEG PAIN; LEG SWELLING; MARE; MUSCULOSKELETAL DISEASE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; SKIN IRRITATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; EDEMA; FEMALE; FORELIMB; HEAT; HORSE DISEASES; HORSES; INFLAMMATION; LAMENESS, ANIMAL; MALE; OINTMENTS; PYRIDONES;

EID: 40549144834     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Adams OR. 1974. Lameness in Horses, ed. 3. Philadelphia, Lea & Febinger, 178-182; 196-205.
2. Al-Bayati MA, Xie Y, Mohr FC, Margolin SB, Giri SN. 2002. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem. Pharmacol. 64: 517-525.
3. Auer DE, Ng JC, Seawright AA. 1993. Free radical oxidation products in plasma and synovial fluid of horses with synovial inflammation. Aus. Vet. J. 70: 49-52.
4. Bertone AL, Palmer JL, Jones J. 2001. Synovial fluid cytokines and eicosanoids as markers of joint disease in horses. Vet. Surg. 30: 528-538.
5. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin SB, Lefkowitz SS. 1998. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Intl J. Immunopharmacol. 20: 685-695.
6. Caron JP, Kaneene JB, Miller R. 1996. Results of a survey of equine practitioners on the use and perceived efficacy of polysulfated glycosaminoglycan. J. of Am. Vet. Med. Assoc. 209: 1564-1568.
7. Collins EA. 1989. Use of polysulphated glycosaminoglycan in equine lameness. Vet. Rec. 124: 89-90.
8. Dabareiner RM, Carter GK, Honnas CM. 2003. Injection of corticosteroids, hyaluronate, and amikacin into the navicular bursa in horses with signs of navicular area pain unresponsive to other treatments: 25 cases (1999-2002). J. Am. Vet. Med. Assoc. 223: 1469-1474.
9. De La Calle J, Burba DJ, Ramaswamy CM, Hosgood G, Williams J, LeBlanc C, Moore RM. 2002. Plasma and synovial fluid endothelin-1 and nitric oxide concentrations in horses with and without joint disease. Am. J. Vet. Res. 63: 1648-1654.
10. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Carbona H, Calis KA, Gochuico B. 2002. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. 76: 234-242.
11. Garcia L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin SB, Armendariz-Borunda J. 2002. Pirfenidone effectively reverses experimental liver fibrosis. J. Hepatol. 37: 797-805.
12. Giri SN, Al-Bayati MA, Du X, Schlegle E, Mohr FC, Margolin SB. 2004. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Cancer Chemother. Pharmacol. 53: 141-150.
13. Giri SN, Leonard S, Shi X, Margolin SB, Vallyathan V. 1999. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Path. Toxicol. Oncol. 18: 169-177.
14. Goodman N, Moderator; Panelists; L. Bramlage, J. Foerner, W. McIlwraith, V. Snow. Lameness, Equine Roundtable Discussion. Equ. Prac. 1990, 12: 28;
15. 1991, 13: 33-37.
16. Gurujeyalakshimi G, Hollinger MA, Giri SN. 1999. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol., 276: (Lung Cell Mol Physiol 20): L311-L318.
17. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG. 2002. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Inft. Immun. 70: 2989-2994.
18. Iyer SN, Du X, Norris C, Margolin SB, Giri SN. 2003. Effects of pirfenidone on inflammatory and anti-inflammatory cytokines, CD4 and CD8 T-cells and nitric oxide levels in the bronchoalveolar lavage fluid in bleomycin mouse model of pulmonary fibrosis. Am. J. Resp. Crit. Care Med. 167: 621.
19. Iyer SN, Wilds JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. 1995. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 125: 779-785.
20. Iyer SN, Gurujeyalakshmi G, Giri SN. 1999. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 291: 367-373.
21. Iyer SN, Hyde DM, Giri SN. 2000. Anti-inflammatory effects of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation, 24: 477-491.
22. Kallings P. 1993. Nonsteroidal anti-inflammatory drugs. Vet. Clin. North Am. Equ. Prac. 9: 523-541.
23. Lindholm AC, Swensson U, De Mitri N, Collinder E. 2002. Clinical effects of betamethasone and hyaluronan, and of defocalized carbon dioxide laser treatment on traumatic arthritis in the fetlock joints of horses. J. Vet. Med. A: Physiol. Pathol. Clin. Med. 49: 189-194.
24. McIlwraith CW. 1989. Traumatic arthritis and its treatment in the athletic horse. The Equ. Athlete, 2: 1-16
25. Mirkovic S, Seymour AL, Fenning A, Strachan A, Margolin SB, Taylor SM, Brown L. 2001. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br. J. Pharmacol. 135: 961-968.
26. Misra HP, Rabideau C. 2000. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell Biochem. 204: 119-126
27. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. 2002. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur. J. Pharmacol. 446: 177-185.
28. Owens JG, Kamberling SG, Stanton SR, Keowen ML. 1995. Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Equ. Vet. J. 27: 296-300.
29. Owens JG, Kamberling SG, Stanton SR, Keowen ML, Prescott-Mathews JS. 1996. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Am. J. Vet. Res. 57: 866-874.
30. Passeron F. 2004. Comparison of various ointment concentrations of pirfenidone topically applied to experimental dermal lesions in mice. In: Investigational New Drug Brochure for Pirfenidone, prepared: S.B. Margolin, and S.N. Giri, Marnac, Inc., Dallas, TX p.161.
31. Passeron F. 2004. Comparison of 5% and 10% pirfenidone ointment against experimentally-induced dermal inflammation in pregnant mares. In: Investigational New Drug Brochure for Pirfenidone, prepared: S.B. Margolin, and S.N. Giri, Marnac, Inc., Dallas, TX p. 164.
32. Patterson AW. 1980. Memorandum Reference: NDDA 47-925, Domoso Gel (DMSO), Syntex Laboratories, July 15.
33. Pesce E, Struma E, Giri SN, Margolin SB. 2004. Anti-rheumatic effect of pirfenidone in a double-blind clinical pilot trial in humans. Res. Comm. Pharmacol. Toxicol. (in press).
34. Raghu G, Johnson WC, Lockhart D, Mageto Y. 1999. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am. J. Resp. Crit. Care Med. 159: 1061-1069.
35. Robbins SL, Cotran RS, Komar V. 1984. Pathologic Basis of Disease, ed. 6, Philadelphia, WB Saunders Co. 40-84.
36. Seino KK, Foreman JH, Greene A, Goetz TE, Benson GJ. 2003. Effects of topical perineural capsaicin in a reversible model of equine foot lameness. J. Vet. Inter. Med. 17: 563-566.
37. Sloet Van Oldruitenborgh-Oosterbann MM. 1999. Laminitis in the horse: a review. Veterinary Quarterly, 21: 121-127.
38. Stasher TS. 1987. Adams Lameness in Horses, ed. 4. Philadelphia, Lea & Febinger. 614-615.
39. Waller JR, Toomey D, Metcalfe MS, Margolin SB, Nicholson ML. 2002. Pirfenidone inhibits early neointimal proliferation following arterial injury. Transplant Proc. 34: 1486-1488.
40. Weiss DJ, Evanson OA, McClenahan D, Fagliari JJ, Dunnwiddie CT, Wells RE. 1998. Effect of a competitive inhibitor of platelet aggregation on experimentally induced laminitis in ponies. Am. J. Vet. Res. 59: 814-817.